drugset / Trial / NCT01710345

Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy

NCT01710345

Phase 2 Completed 101 enrolled Talphera, Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a dose-finding study to determine if the sublingual administration of the Sufentanil NanoTab is safe and effective in the treatment of post-operative pain.

Timeline

Start
2012-10
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Sufentanil Other / unclassified 20 ug Subcutaneous
Subject Sufentanil Other / unclassified 30 ug Subcutaneous

Indications

No indication recorded.